Transformation of competent Bacillus subtilis lysogenic for SP02 with any of three plasmids (pCM194, pUB110, pAM77) generates drug-resistant transformants of which 5 to 20% have lost the infectivity and immunity associated with the SP02 prophage. Such cured derivatives can be again lysogenized with SP02 and again cured by introduction of a different plasmid. Elimination of the SP02 prophage was not detected when plasmids were introduced by PBS1 transduction or by transformation of protoplasts. Similarly, transformants of B. subtilis selected for chromosome markers retained the prophage. The 105 prophage was not eliminated from competent B. subtilis transformed with plasmids.
Transformation of competent Bacillus subtilis lysogenic for SP02 with any of three plasmids (pCM194, pUB110, pAM77) generates drug-resistant transformants of which 5 to 20% have lost the infectivity and immunity associated with the SP02 prophage. Such cured derivatives can be again lysogenized with SP02 and again cured by introduction of a different plasmid. Elimination of the SP02 prophage was not detected when plasmids were introduced by PBS1 transduction or by transformation of protoplasts. Similarly, transformants of B. subtilis selected for chromosome markers retained the prophage. The 105 prophage was not eliminated from competent B. subtilis transformed with plasmids.
Methods for eliminating prophages from Bacillus subtilis require the use of procedures that kill cells (1) or involve curing resulting from genetic crosses between a nonlysogenic donor and a lysogenic recipient. During our studies of SP02 lysogenic derivatives of B. subtilis, we sought a rapid and simple method for eliminating the prophage while causing a minimal genetic alteration in the host. In the present report, we demonstrate that transformation of plasmids into an SP02 lysogen results in high-frequency elimination of the prophage from the resulting transformant clones.
Procedures and media for propagation and plaque assays of SP02 and 4105 have been described (8) . B. subtilis strains BR151 (trpC2 metBlC lys-3), JH86T (phe-1 spoB), and Kiti (cysA14 purA trpC2) were used (6, 8; R. Dedonder, personal communication). Cells were rendered competent for transformation by the Bott and Wilson procedure (2) . Protoplast transformation was by the method of Chang and Cohen (3). PBS1 transduction was as previously described (6) . Plasmids pUB110, pCM194 and pAM77 have been described (5, 12) . Isolation and purification of plasmid DNA was as previously described (7 (SP02) or Kitl (SP02) with purified DNA of plasmids pCM194, pUB110, or pAM77 generated antibiotic-resistant transformant clones of which 5 to 22% had acquired sensitivity to SP02C; these sensitive clones failed to exhibit killing activity when transferred to lawns of BR151 (Table 1) . More than 600 pCM194-or pUB110-containing transductants of BR151 (SP02), generated with phage PBS1, were all immune to infection by SP02C. Similarly, introduction of pCM194 into BR151 (SP02) protoplasts failed to eliminate the prophage from more than 500 transformant clones examined.
The absence of the SP02 prophage from the majority of "plasmid-cured" transformants was inferred by the loss of superinfection immunity to SP02 and loss of production of infectious SP02 particles. Three derivatives of BR151 (SP02) cured of the prophage by transformation with pUBI were also found to lack SP02 homologous sequences that were readily detectable in DNA from BR151 (SP02) (Fig. 1) .
SP02-cured clones of BR151 generated by transformation with pCM194 or pUB110 retained the nutritional requirement of BR151, and each of several tested could be relysogenized by SP02. One derivative of BRI51 (SP02) cured of SP02 by transformation with pCM194 was relysogenized with SP02 and then transformed with the compatible plasmid pUB110. Of 200 neomycin-resistant transformants examined, 32 were sensitive to SP02C, and these 32 did not exhibit killing activity when transferred to lawns of BR151. Thus, cells can be plasmid cured of SP02, relysogenized, and then cured again.
pAM77 specifies resistance to erythromycin. This plasmid was originally detected in Streptococcus species but replicates in B. subtilis (11) . pAM77 is unstable in B. subtilis in the absence of continued selection for erythromycin resistance; greater than 90% of the colonies resulting from overnight growth of BR151 (pAM77) in drug-free Penassay broth are erythromycin sensitive. Transformation of pAM77 into BR151 (SP02) results in transformant clones lacking the SP02 prophage (Table 1) . Subsequent growth of a pAM77-containing, SP02-cured derivative of BR151 in drug-free broth allows regeneration of BR151 free of both the prophage and the "curing" plasmid.
We could not eliminate the SP02 prophage by transformation of BR151 (SP02) with B. subtilis chromosome DNA (from JH86T) regardless of whether the marker selected was tryptophan, methionine, or lysine (see Table 1 ). This did not appear to be due to the minimal media used for selection, since 18% of the pUBllO transformants of BR151 (SP02) selected on minimal media (supplemented with tryptophan, lysine, and methionine) containing 10 Hybridization of nick-translated SP02 DNA to Sst-1-generated fragments of DNA from BR151, BR151 (SP02), and BR151 cured of SP02 by plasmid transformation. BR151 (SP02) was transformed with pUB110, and a neomycin-resistant derivative cured of the prophage was identified (see Table 1 ). DNA from this cured lysogen (well 1), BR151 (SP02) (well 2), and BR151 (well 3) was isolated by a phenol procedure (8) 
